Clinical Trials Logo

Scleroderma, Limited clinical trials

View clinical trials related to Scleroderma, Limited.

Filter by:
  • None
  • Page 1

NCT ID: NCT06425653 Completed - Clinical trials for Scleroderma, Systemic

Exercise With Scleroderma Functional Outcomes

Start date: February 5, 2021
Phase: N/A
Study type: Interventional

The study aims to investigate the effects of an exercise program applied to patients with scleroderma on functional outcomes (hand and mouth functional results and quality of life).

NCT ID: NCT04927390 Active, not recruiting - Systemic Sclerosis Clinical Trials

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

MINIMISE
Start date: December 8, 2021
Phase: Phase 2
Study type: Interventional

Systemic sclerosis or scleroderma is an autoimmune condition that cause thickening and hardening of the skin, but can also affect internal organs. There are two major subsets of scleroderma: the limited cutaneous systemic sclerosis (lcSSc) that usually affects the skin of the face, neck, lower legs or lower arms, but can also lead to internal organ complications, and the diffuse cutaneous systemic sclerosis (dcSSc) that may affect blood circulation and internal organs, as well as the skin. To date there is no drug that has been definitively proven to cure or modify the course of scleroderma. However, there is emerging evidence that immunosuppression and specifically mycophenolate mofetil (MMF) may be beneficial in lcSSc. The MINIMISE-Pilot trial would be an important first step to evaluate the risk and potential benefit to this disease group. MMF as the intervention of choice is both appropriate and timely, as it has been routinely used in the management of dcSSc. The aim of this pilot trial is to explore whether the immunosuppressive agent MMF can slow down disease progression in patients with lcSSc compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management.

NCT ID: NCT02682511 Recruiting - Autoimmune Diseases Clinical Trials

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Start date: January 2017
Phase: Phase 2
Study type: Interventional

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

NCT ID: NCT02531009 Withdrawn - Healthy Clinical Trials

Systemic Sclerosis Clinical and Biomarker Study

Start date: December 2015
Phase: N/A
Study type: Observational

The primary objective of the study is to assess the change in systemic sclerosis (SSc)-associated gastrointestinal (GI) tract symptoms over a 1-year period in participants with SSc.

NCT ID: NCT01881529 Completed - Diffuse Scleroderma Clinical Trials

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Start date: April 2013
Phase: N/A
Study type: Observational

To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.

NCT ID: NCT01347008 Recruiting - Clinical trials for Scleroderma, Systemic

Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis

Start date: April 2011
Phase: Phase 3
Study type: Interventional

Early phases of systemic sclerosis is characterized by inflammatory and microvasculature alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance vasculogenesis. The purpose of this study is to evaluate the effect of sildenafil citrate on hand blood flow of patients with systemic sclerosis, using Laser Doppler Imaging.